Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

554 - Modified FOLFOX-6 as 1st line therapy for adenocarcinoma of unknown primary: a multicenter phase II study


19 Dec 2015


Poster presentation 1


Dong-Yeop Shin


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


D. Shin1, H. Lee2, I.I. Na2, Y.J. Yuh3, B.S. Kim4, I.J. Chung5, W. Bae5, H. Shim5, E. Song6, S.H. Yang2, H.J. Kang2

Author affiliations

  • 1 Internal Medicine, Korea Institute of Radiological & Medical Sciences, 139-706 - Seoul/KR
  • 2 Internal Medicine, Korea Institute of Radiological & Medical Sciences, Seoul/KR
  • 3 Internal Medicine, Sanggye Paik Hospital, Seoul/KR
  • 4 Internal Medicine, Veterance Hospital, Seoul, Seoul/KR
  • 5 Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun-Gun/KR
  • 6 Internal Medicine, Chonbuk National University Medical School, Jeon Ju/KR


Abstract 554


The aim of the study was to assess the clinical activity and toxicity of oxaliplatin and leucovorin in combination with bolus and continuous infusion of 5-fluorouracil treated every 2 weeks (modified FOLFOX-6 regimen) in patients with adenocardinoma of unknown primary (ACUP).


Previously untreated ACUP patients were enrolled and treated with oxaliplatin 100mg/m2 and leucovorin 200mg/m2 simultaneously as 2-hour infusion followed by bolus administration of 5-fluorouracil 400mg/m2 and continuous infusion of 5-fluorouracil 2400mg/m2 every 2 weeks. Response evaluation was performed every 3 cycles according to the response assessment in solid tumours version 1.1, and toxicities were assessed using the National Cancer Institute Common Toxicity Criteria for adverse events version 3.0 every 2 weeks.


Data from 23 patients who had been enrolled in this multicenter phase II trial between May 2009 and Nov 2014 was collected for an interim analysis. A total of 134 cycles of modified FOLFOX-6 were treated in these 23 patients. The median number of cycles of modified FOLFOX-6 was 5 (range, 1–12). Among 20 patients whose tumor responses were evaluable, 7 patients showed partial response (no complete response), which objective response rate was 35.0% (95% confidence interval: 13.2 - 52.9). The median duration of response was 3.9 months (range, 3.0–19.8). Median progression-free survival was 3.0 months (95% CI: 1.8–6.7 months) in whole patients, which was 2.4 months for non-responders and 5.8 months for responders, respectively. Adverse events of all grade occurred in 22 patients (95.7%), and a grade ≥ 3 event occurred in 7 patients (30.4%). Grade ≥ 3 hematologic toxicities occurred in 4 patients (17.4%), and grade ≥ 3 non-hematologic toxicities occurred in 6 patients (26.1%), respectively. Most common hematologic toxicities were anemia and neutropenia (78.3% and 65.2%, respectively), while nausea was most frequent non-hematologic toxicity (47.8%).


Modified FOLFOX-6 showed modest activity in treatment-naïve patients with ACUP. Future prospective large scale study incorporating parallel molecular prediction marker study is warranted.

Clinical trial identification



All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings